Alzheimer's disease, diagnosis and the need for biomarkers

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 317-323

  Hooper, Claudie ^a   Lovestone, Simon ^a   Sainz Fuertes, Ricardo ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

amyloid; Alzheimer's disease; Biomarker; Memory; Neuro imaging; Psycho metric testing; tau

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; COGNITION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; GENE LOCUS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENOTYPE; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; MEMORY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PSYCHOMETRY; RISK FACTOR; VOLUMETRY;

EID: 45749109439     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Agronin, M.E. 2008. Alzheimer's disease and other dementias. Practical guides inPsychiatry. Second Edition. Published by 'Wolters Kluwer/ Lippincott Williams and Wilkins', Philadelphia, U.S.A.
2. Alexander, G.E., Chen, K., Pietrini, P., Rapoport, S.I. and Reiman, E.M. 2002. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am. J. Psychiatry, 159:738-45.
3. Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, R, Hesse, C., Tarvonen, S., Raiha, I., Sourander, L., Winblad, B. and Blennow, K. 1998. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol Neurosurg. Psychiatry, 64:298-305.
4. Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B. and Blennow, K. 2001. Evaluation of CSF-tau and CSF-A(beta) 42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice. Arch. Neurol., 58:373-9.
5. Atkinson, A.J., Colbum, W.A., DeGruttola, V.G., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Peck, C.C., Schooley, R.T., Spilker, B.A., Woodcock, J. and Zeger, S.L. 2001. Biomarkers and surrogate end-points: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69:89-95.
6. Behl, P., Stefurak, T.L. and Black, S.E. 2005. Progress in clinical neurosciences: cognitive markers of progression in Alzheimer's disease. Can. J. Neurol. Sci., 32:140-51.
7. Blennow, K., Wallin, A., Agren, H., Spenger, C., Siegfried, J. and Varimechelen, E. 1995. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease. Mol. Chem. Neuropathol, 26:231-45.
8. Braak, H. and Braak, E. 1998. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural. Transm., 53:127-40.
9. Burns, A., Lawlor, B. and Craig, S. 2004. Assessment scales in Old Age Psychiatry. Second Edition. Published by 'Martin Dunitz Taylor and Francis group'. London and New York.
10. Buxbaum, J.D., Liu, K.N., Luo, Y., Slack, J.L., Stocking, K.L., Peschon, J.J., Johnson, R.S., Castner, B.J., Cerretti, D.P. and Black, R.A. 1998. Evidence That Tumor Necrosis Factor alpha àConverting Enzyme Is Involved in Regulated alpha-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor. J. Biol. Chem., 273:27765-7.
11. De, S.B. 2003. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron, 38:9-12.
12. Desai, M., Stockbridge, N. and Temple, R. 2006. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS. J., 8:E146-52.
13. Dickson, D.W. 1997. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging, 18:S21-6.
14. Du, A.T., Schuff, N., Zhu, X.P., Jagust, W.J., Miller, B.L., Reed, B.R., Kramer, J.H., Mungas, D., Yaffe, K., Chui, H.C. and Weiner, M.W. 2003. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology, 60:481-6.
15. Feldman, H., Gabathuler, R., Kennard, M., Nurminen, J., Levy, D., Foti, S., Foti, D., Beattie, B.L. and Jefferies, W.A. 2001. Serum p97 levels as an aid to identifying Alzheimer's disease. J. Alzheimers. Dis., 3:507-16.
16. Fox, N.C., Cousens, S., Scahill, R., Harvey, R.J. and Rossor, M.N. 2000. Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease: Power Calculations and Estimates of Sample Size to Detect Treatment Effects. Arch. Neurol., 57:339-44.
17. Frederick, B.D., Lyoo, I.K., Satlin, A., Ahn, K.H., Kim, M.J., Yurgelun-Todd, D.A., Cohen, B.M. and Renshaw, P.F. 2004. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 28:1313-22.
18. Goedert, M. 1998. Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Prog. Brain Res., 117:287-306.
19. Goedert, M. and Spillantini, M.G. 2006. A Century of Alzheimer's Disease. Science, 314:777-81.
20. Green, A.J.E., Harvey, R.J., Thompson, E.J. and Rossor, M.N. 1999. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neuroscience Letters, 259:133-5.
21. Hardy, J. 2006. A hundred years of Alzheimer's disease research. Neuron, 52:3-13.
22. Hardy, J.A. and Higgins, G.A. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science, 256:184-5.
23. Harvan, JR. and Cotter, V 2006. An evaluation of dementia screening in the primary care setting. J. Am. Acad. Nurse Pract., 18:351-60.
24. Hawkins, B.T. and Davis, T.P. 2005. The blood-brain barrier/ neurovascular unit in health and disease. Pharmacol. Rev., 57:173-85.
25. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H.C., Riemenschneider, M., Deyn, P.P.D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P.D., Iqbal, K., Pottel, H., Vanmechelen, E. and Vanderstichele, H. 1999. Improved discrimination of AD patients using {beta} -amyloid(1-42) and tau levels in CSF. Neurology, 52:1555.
26. Hye, A., Kerr, F., Archer, N., Foy, C., Poppe, M., Brown, R., Hamilton, G., Powell, J., Anderton, B. and Lovestone, S. 2005. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett., 373:1-4.
27. Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H.L., Hooper, C., Rijsdijk, F., Tabrizi, S.J., Banner, S., Shaw, C.E., Foy, C., Poppe, M., Archer, N., Hamilton, G., Powell, J., Brown, R.G., Sham, P, Ward, M. and Lovestone, S. 2006. Proteome-based plasma biomarkers for Alzheimer's disease. Brain, 129:3042-50.
28. Itoh, N., Arai, H., Urakami, K., Ishiguro, K, Ohno, H,, Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., Moeller, H.J., Imagawa, M., Kohno, H., Nakashima, K., Kuzuhara, S., Sasaki, H. and Imahori, K. 2001. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol, 50:150-6.
29. Kaye, J.A., Swihart, T., Howieson, D., Dame, A., Moore, M.M., Karnos, T., Camiciol i, R., Ball, M., Oken, B. and Sexton, G. 1997. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology, 48:1297-304.
30. Kimberly, W.T., LaVoie, M.J., Ostaszewski, B.L., Ye, W., Wolfe, M.S. and Selkoe, D.J. 2003. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. U.S.A., 100:6382-7.
31. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A. and Langstrom, B. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol., 55:306-19.
32. Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M, Haass, C. and Fahrenholz, F. 1999. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. PNAS, 96:3922-7.
33. Li, T., Ma, G., Cai, H., Price, D.L. and Wong, PC. 2003. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. J. Neurosci., 23:3272-7.
34. Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L.J., Ferri, C., Casadei, V. and Grimaldi, L.M. 2000. Increased plasma levels of interleukin-1, interleukin-6 and alpha- 1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain. J. Neuroimmunol., 103:97-102.
35. Lockhart, A., Lamb, J.R., Osredkar, T., Sue, L.I., Joyce, J.N., Ye, L., Libri, V., Leppert, D. and Beach, T.G. 2007. PIB. is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis. Brain, 130:2607-15.
36. Lovestone, S. 2006. Biomarkers in Alzheimer's disease. J. Nutr. Health Aging, 10: 118-22.
37. Lovestone, S., Francis, P. and Strandgaard, K. 2007a. Biomarkers for disease modification trials - the innovative medicines initiative and Add NeuroMed. J Nutr Health Aging, 11:359-61.
38. Lovestone, S., Guntert, A., Hye, A., Lynham, S., Thambisetty, M. and Ward, M. 2007b. Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. Expert. Rev. Proteomics, 4:227-38.
39. Mattson, M.P. 2004. Pathways towards and away from Alzheimer's disease. Nature, 430:631-9.
40. Meyerhoff, D.J., MacKay, S., Constans, J.M., Norman, D., Van D, C., Fein, G. and Weiner, M.W. 1994. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann. Neurol., 36:40-7.
41. Nagga, K., Gottfries, J., Blennow, K. and Marcusson, J. 2002. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(I-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord., 14:183-90.
42. Nordberg, A. 2007. Amyloid imaging in Alzheimer's disease. Curr. Opin. Neurol., 20:398-402.
43. Parnetti, L., Lanari, A., Amici, S., Gallai, V, Vanmechelen, E. and Hulstaert E 2001. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol. Sci., 22:77-8.
44. Persidsky, Y., Ramirez, S.H., Haorah, J. and Kanmogne, G.D. 2006. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune. Pharmacol., 1123-36.
45. Pratico, D., Clark, C.M., Lee, V.M., Trojanowski, J.Q., Rokach, J. and FitzGerald, G.A. 2000. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol., 48:809-12.
46. Ray, S., Britschgi, M., HerbeM C., Takeda-Uchimura, Y, Boxer, A., Blennow, K, Friedman, L.F., Galasko, DR., Jutel, M., Karydas, A., Kaye, J.A., Leszek, J., Miller, B.L., Minthon, L., Quinn, J.F., Rabinovici, G.D., Robinson, W.H., Sabbagh, M.N., So, Y.T., Sparks, D.L., Tabaton, M., Tinklenberg, J., Yesavage, J.A., Tibshirani, R. and Wyss-Coray, T. 2007. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med., 13:1359-62.
47. Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., Dickinson, K.L., Maruff, R, Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-Danguy, H., O'Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L. and Villemagne, V.L. 2007. Imaging {beta}-amyloid burden in aging and dementia. Neurology, 68:1718-25.
48. Rush, J.A., Pincus, A.H., First, M.B., Blacker, D., Endicott, J., Keith, S.J., Phillips, K.A., Ryan, N.D., Smith, R.G., Tsunag, M.T., Widiger, T.A. and Zarin, D.R. 2000. Handbook of Psychiatric Measures. Published by the 'American Psychiatric Association' Washington DC, USA.
49. Saunders, A.M., Strittmatter, W.J., Schmechel, D., George-Hyslop, P.H., Pericak-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlan, D.R. and Alberts, M.J. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology, 43:1467-72.
50. Scheuner, D., Eckman, C., Jensen, M., Son&, X., Citron, M., Suzuki, N., Bird, T.D., Hardy, J., Hutton, M., Kukull, W, Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W, Lannfelt, L., Selkoe, D. and Younkin, S. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med., 2:864-70.
51. Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D'Agostino, R.B., Wilson, P.W. and Wolf, PA. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med., 346:476-83.
52. Silbert, L.C., Quinn, J.E, Moore, M.M., Corbridge, E., Ball, M.J., Murdoch, G., Sexton, G. and Kaye, J.A. 2003. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurvlogv, 61:487-92.
53. Sjogren, M., Minthon, L., Davidsson, R., Granerus, A-K., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A. and Blennow, K. 2000. CSF levels oftau, beta-amyloid(1-42) and GAP-43 in fronto-temporal dementia, other types of dementia and normal aging. J. Neural. Transm., 107:563-79.
54. Steiner, H., Duff, K., Capell, A., Romig, H., Grim, M.G., Lincoln, S., Hardy, J., Yu, X., Picciano, M., Fechteler, K., Citron, M., Kopan, R., Pesold, B., Keck, S., Baader, M., Tomita, T., Iwatsubo, T., Baumeister, R. and Haass, C. 1999. A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J. Biol. Chem., 274:28669-73.
55. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S. and Roses, A.D. 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 alleie in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A., 90:1977-81.
56. Tanzi, R.E. and Bertram, L. 2005. Twenty years ofthe Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 120:545-55.
57. Thomas, A. 2008. Clinical Aspects of dementia: Alzheimer's disease. In 'Oxford textbook of old age psychiatry. Edited by Jacoby R., Oppenheimer C., Dening, T., Thomas, A. Published by 'Oxford University Press', Oxford, U.K.
58. Van Broeckhoven, C.L. 1995. Molecular genetics of Alzheimer disease: identification of genes and gene mutations. Eur. Neurol., 35:8-19.
59. Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., van d, V., Martin, J.J. and Cras, P. 1993. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem., 61:1828-34.
60. Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjogren, M., Andreasen, N. and Blennow, K. 2000. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopep- tide for standardization. Neuroscience Letters, 285:49-52.
61. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins, F., Treanor, J., Rogers, G. and Citron, M. 1999. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286:735-41.
62. Vigo-Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B. and Lieberburg, I. 1995. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology, 45:788-93.
63. Wolfe, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T. and Selkoe, D.J. 1999. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 398:513-7.
64. Yoshizawa, T., Yamakawa-Kobayashi, K., Komatsuzaki, Y., Arinami, T., Oguni, E., Mizusawa, H., Shoji, S. and Hamaguchi, H. 1994. Dose-dependent association of apolipoprotein E allele epsilon 4 with late-onset, sporadic Alzheimer's disease. Ann. Neurol., 36:656-9.